Retrospective Analysis of Drug Disposition and Response-related Genotypes in Cancer Patients and Correlation With Pharmacokinetics and Pharmacodynamics Data
Genetic polymorphisms in drug-metabolizing enzymes, transporter/receptors, and transcription
factors might affect an individual's response to drug therapy.
Interindividual differences in efficacy and toxicity of cancer chemotherapy are especially
important given the narrow therapeutic index of these drugs.
During analysis of investigational agents, interindividual variances in pharmacokinetics and
pharmacodynamics are often noted. It is often wondered if these variances might in part be
explained by genetic differences in drug metabolizing enzymes, transporters.
To better understand the genotype-phenotype relationship, additional analysis correlating
pharmacokinetic data with relevant genotyping.
All individuals previously enrolled on IRB approved clinical trials at the National Cancer
In these retrospective studies, the association between an individual's pharmacokinetic
profile and the genetic variation in their drug metabolizing enzymes and other critical
regulators of gene expression will be investigated.
The hypothesis that an individual's genotypic constitution may be associated with clinical
response and/or toxicity will be explored.
William D Figg, Pharm.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Cancer Institute (NCI), 9000 Rockville Pike||Bethesda, Maryland 20892|